Oncimmune Regulatory News (ONC)

2 FEBRUARY 2024

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Notice of Annual General Meeting

Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry enabling precision medicine, today gives notice that its Annual General Meeting ("AGM") will be held at 10:00am GMT on 26 February 2024 at the offices of Singer Capital Markets, 1 Bartholomew Lane, London, EC2N 2AX.

The Notice of AGM has been sent to shareholders and can also be viewed on the "Investors" section of the Company's website at www.oncimmune.com.

The audit process for the Company's financial results for the 12 months ended 31 August 2023 ("FY2023") is continuing in the ordinary course and the Company expects its annual report, including the financial statements for FY2023, to be published by the end of February 2024 and for this to be laid before a separate general meeting in March 2024.

For further information:

Oncimmune Holdings plc

contact@oncimmune.com

Singer Capital Markets (Nominated Adviser and Broker)

Philip Davies, Harry Gooden, James Fischer

+44 (0)20 7496 3000

Zeus (Joint Broker)

Dominic King, Victoria Ayton, Dan Bate

+44 (0)20 3829 5000

+44 (0)20 3727 1000

About Oncimmune

Oncimmune is a precision medicine company, specialising in analysing immune interactions through the autoantibody profile. Taking a platform approach to generating insights, Oncimmune is partnering with global pharmaceutical and biotech companies, as well as contract research organisations (CROs) to discover novel biomarkers for the development of more targeted and effective therapies across many immune-mediated diseases. Our mission at Oncimmune is to enable precision medicine. We help our partners to discover novel biomarkers, drug targets and predict treatment efficacy through the application of our platform. We are able to do this by deploying our world class scientific team and our cutting-edge technology platform, built on years of experience in the field. Our aim is to make this an essential tool in drug discovery and development.

Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.

For more information, visit www.oncimmune.com